ALPHA1-PROTEINASE INHIBITOR DEFICIENCY

Clinical trials for ALPHA1-PROTEINASE INHIBITOR DEFICIENCY explained in plain language.

Never miss a new study

Get alerted when new ALPHA1-PROTEINASE INHIBITOR DEFICIENCY trials appear

Sign up with your email to follow new studies for ALPHA1-PROTEINASE INHIBITOR DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Three-Year quest to slow lung destruction in genetic emphysema

Disease control Not yet recruiting

This study aims to find the most effective dose of an existing medication (Respreeza/Zemaira) to slow the progression of lung damage in adults with emphysema caused by Alpha-1 antitrypsin deficiency. Over 270 participants will receive weekly intravenous infusions for three years …

Matched conditions: ALPHA1-PROTEINASE INHIBITOR DEFICIENCY

Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

ALPHA1-PROTEINASE INHIBITOR DEFICIENCY

Get alerted when new ALPHA1-PROTEINASE INHIBITOR DEFICIENCY trials appear

Three-Year quest to slow lung destruction in genetic emphysema